Objective: A previous phase I trial in 14 pretreated patients with progressive advanced colorectal cancer demonstrated 750 mg/m 2 to be the maximum tolerable dose of 5-fluorouracil (5-FU) administered as a five-day continuous infusion modulated by short infusions of 100 mg/m 2 folinic acid twice daily. The dose-limiting toxicities were hand-foot syndrome and severe mucositis. A response rate of 21% and 50% stable disease could be achieved. In order to determine the effectiveness and tolerability, we initiated a multicenter phase II trial applying a 650 mg/m 2 recommended dose of 5-FU and 100 mg/m 2 folinic acid twice daily every three weeks. Patients and methods: From January 1994 to July 1996, 88 advanced and progressive colorectal cancer patients either previously treated with a bolus schedule of 5-FU and folinic acid (34 patients) or without (54 patients) previous chemotherapy were included in this trial.
Introduction
Clinical trials on disseminated cancer of the large bowel have focused on increasing the efficacy of 5-fluorouracil (5-FU) by applying folinic acid as biochemical modulator and changing the schedule or enhancing the dose intensity [1] . Despite major efforts, the optimum schedule for administering 5-FU modulated by folinic acid is still unclear. In prospectively randomized trials, the administration of 5-FU as continuous infusion with or without modulation by folinic acid seemed to be superior to bolus administration with regard to the remission rates [2] . However, the optimal schedule of 5-FU as continuous has not yet been defined and ranges from 24 hours to four weeks [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Based on these considerations, we initiated a phase I study [3] , administering 5-FU as a five-day continuous infusion combined with a five-day short term infusion of folinic acid 100 mg/m 2 twice daily in order to increase the efficacy [4] . In 14 pretreated patients with progressive colorectal cancer, we demonstrated 750 mg/m 2 daily to be the maximum tolerable dose of 5-FU. The limiting toxic effects were severe hand-foot syndrome and mucositis. The therapy regimen achieved an overall response of 21% while stable disease could be induced in 50% of the patients. We initiated a multicenter phase II trial, applying a recommended 650 mg/m 2 dose of 5-FU daily as a fiveday continuous infusion combined with folinic acid 100 mg/m 2 twice daily to examine whether this schedule is effective as first-or second-line chemotherapy in advanced and progressive colorectal cancer. Figure I . Kaplan-Meier survival projection from the start of treatment in all 88 patients (median survival time 13.7 months in nonpretreated and 14 months in pretreated patients).
Patients and methods
Eighty-eight eligible patients with progressive colorectal cancer as determined by two independent observations and confirmed by computer tomographic scan, X-ray or ultrasound, either with (34 patients) or without (54 patients) previous chemotherapy, were admitted to this phase II trial. Pretreatment consisted of a weekly bolus regimen of 5-FU modulated by FA or interferon-o-2b. The median duration of response to this first line chemotherapy was 119 days (range 23-367 days). The median duration between first and our second line treatment was 49 days (range 5-571 days). Prior to chemotherapy, patients underwent a subcutaneous port insertion and received the 5-FU infusions via portable infusion pumps. A therapeutic course consisted of a five-day continuous infusion of 5-FU (650 mg/m 2 daily) and folinic acid (100 mg/m 2 ) administered every 12 hours from day 1-5 as short term infusion. The course was repeated starting on day 22. Therapy was continued until progression occurred. The response was assessed after every second therapeutic course according to WHO criteria. All patients provided informed consent according to the ethics committee guidelines of the Benjamin Franklin Medical Center.
Results
Therapy led to one complete remission (3% CR) and one partial remission (3% PR) within the group of pretreated patients (« = 34). Twenty-three patients (68% SD) had a stable disease, and nine patients (26% PD) progressed during chemotherapy. The median time to progression was 5.8 months and the estimated survival time was 14 months (Figure 1 ). Response to first-line chemotherapy and this second-line regimen correlated significantly (r = 0.4627; P = 0.046), indicating that particularly those patients showing a response to prior chemotherapy have a better chance of again achieving a stable disease.
In the group of nonpretreated patients (n = 54), one had a complete response (2% CR) and seven a partial response (13% PR). Thirty-six patients had a stable disease course (67% SD), and ten patients (18% PD) progressed despite therapy. Kaplan-Meier analysis yielded an estimated median survival time of 13.7 months (Figure 1) . The median time to progression was eight months.
Severe mucositis seemed to be the main limiting toxicity with 3% grade 4 and 15% grade 3 mucositis in the pretreated patients and 10% grade 3 mucositis in the nonpretreated ones. 
Discussion
In our multicenter phase II study, a recommended daily dosage of 650 mg/m 2 5-FU was applied as a five-day continuous infusion and 100 mg/m 2 folinic acid twice daily. The therapy was well tolerated and treatmentinduced toxicity was no reason for delay between subsequent cycles. The 15% remission rate in nonpretreated patients observed with this regimen was clearly inferior to that reported by others ranging from 24% to 58% using continuous infusion of 5-FU and folinic acid [6] [7] [8] [9] [10] [11] [12] [13] [14] . However, the median 13.7-months survival was similar to results reported by others (10-18 months). Based on a recent meta-analysis [5] comparing the efficacy of 5-FU versus 5-FU modulated by folinic acid in advanced colorectal cancer, it was postulated that an improved response rate in patients with a measurable disease course does not automatically translate into a survival benefit and that survival, not tumor response, should therefore be considered as valid end point in future clinical trials.
A weekly regimen of 2.6 g/m 2 5-FU and folinic acid 500 mg/m 2 as 24 h continuous infusion, first described by Ardalan et al. [6] achieved an overall response rate of 58% and a median survival of more than 22 months in nonpretreated patients. Despite a 30% remission rate in previously treated patients, the median survival dropped to 10 months.
The same weekly regimen used as second-line therapy induced remisson in 9% and a stable disease course in 56% of the patients with a median survival of eight months [15] . Our trial in 34 previously treated patients yielded similar results for the remission rate with an overall response rate of 6% and 67% stable disease course and induced a median survival of 14 months.
In conclusion, these results suggest that therapy with a five-day continuous infusion of 5-FU and pulsed folinic acid has a favorable influence on survival in patients pretreated with a 5-FU bolus schedule. With regard to the low toxicity, high stable disease rate and the favorable survival, a five-day continuous infusion of 5-FU 650 mg/m 2 daily together with folinic acid 100 mg/m 2 twice daily may be a reasonable salvage chemotherapy for pretreated patients with progressive metastatic colorectal cancer. As a first-line chemotherapy, this therapeutic regimen does not seem to be superior to weekly regimens applying 24-or 48-hour continuous infusion of 5-FU and folinic acid.
